- Home
- MIST vs PRLD Comparison
MIST vs PRLD Comparison
Compare MIST & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- PRLD
- Stock Information
- Founded
- MIST 2003
- PRLD 2016
- Country
- MIST Canada
- PRLD United States
- Employees
- MIST N/A
- PRLD N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- MIST Health Care
- PRLD Health Care
- Exchange
- MIST Nasdaq
- PRLD Nasdaq
- Market Cap
- MIST 53.9M
- PRLD 50.1M
- IPO Year
- MIST N/A
- PRLD 2020
- Fundamental
- Price
- MIST $1.11
- PRLD $0.78
- Analyst Decision
- MIST Strong Buy
- PRLD Strong Buy
- Analyst Count
- MIST 2
- PRLD 2
- Target Price
- MIST $9.50
- PRLD $4.50
- AVG Volume (30 Days)
- MIST 1.6M
- PRLD 110.2K
- Earning Date
- MIST 05-20-2025
- PRLD 05-06-2025
- Dividend Yield
- MIST N/A
- PRLD N/A
- EPS Growth
- MIST N/A
- PRLD N/A
- EPS
- MIST N/A
- PRLD N/A
- Revenue
- MIST N/A
- PRLD $7,000,000.00
- Revenue This Year
- MIST N/A
- PRLD N/A
- Revenue Next Year
- MIST N/A
- PRLD N/A
- P/E Ratio
- MIST N/A
- PRLD N/A
- Revenue Growth
- MIST N/A
- PRLD N/A
- 52 Week Low
- MIST $0.63
- PRLD $0.61
- 52 Week High
- MIST $2.75
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- MIST 43.96
- PRLD 46.96
- Support Level
- MIST $1.28
- PRLD $0.73
- Resistance Level
- MIST $1.32
- PRLD $1.00
- Average True Range (ATR)
- MIST 0.12
- PRLD 0.09
- MACD
- MIST 0.02
- PRLD -0.01
- Stochastic Oscillator
- MIST 27.39
- PRLD 18.96
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.